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     INTRODUCTION 
  Plasmodium falciparum   malaria is a major public health 
challenge and a serious impediment to socioeconomic devel-
opment, particularly in sub-Saharan Africa, where 85% of the 
global burden occurs. An estimated 0.9 million deaths caused 
by malaria occur each year, and 89% of deaths occurr in chil-
dren less than five years of age and in pregnant women liv-
ing in malaria-endemic areas.  1   Efforts expended to curb the 
burden with available antimalarial drugs, insecticides, and bed 
nets have met with some success. To be effective, a multifaceted 
malaria eradication program should include vaccination and 
effective control of mosquito vectors.  2   The continued spread 
and persistence of   P. falciparum   malaria is caused in part by 
the development of anti-malarial drug resistance, primarily 
against those drugs targeting the parasite asexual erythrocytic 
stages. This stage is also responsible for pathologic and clini-
cal manifestations of the disease.  3   Thus, the need to develop 
alternative approaches to target this life stage with an effec-
tive vaccine is urgent. 
  The extensive genetic diversity of the malaria parasite con-
stitutes major drawbacks to the development of a successful 
malaria vaccine.  4,  5   Such extensive antigenic polymorphism 
greatly enhances the parasites ability to evade immune recog-
nition, making it difficult to elicit adequate responses against 
the full range of variants circulating in the parasite popula-
tion.  6   Fluctuations in genetic diversity across transmission 
seasons can further complicate control measures.  7–  9   Previous 
studies using microsatellite loci have shown significant geo-
graphic variation in genetic diversity between and within 
continents.  10–  12   An in-depth understanding of the distribution 
and dynamics of vaccine candidate antigen diversity in natu-
ral parasite populations is vital for designing a successful and 
broadly deployable malaria vaccine, as well as providing use-
ful clues for interpretation of responses to the vaccine. Several 
  P. falciparum   stage-specific antigens have been character-
ized as vaccine candidates through molecular epidemiology. 
Characterization of the distribution of malaria parasite antigen 
genotypes circulating in a wide geographic area may provide 
important genetic information helpful for malaria vaccines 
design. We have analyzed the genetic diversity of three anti-
gens with promise as vaccine candidates: erythrocyte binding 
antigen 175 (EBA-175), apical membrane antigen (AMA-1), 
and merozoite surface protein 3 (MSP-3). 
  Plasmodium falciparum   EBA-175 antigen plays a central 
role in erythrocyte invasion by sialic acid–dependent binding 
to glycophorin A. It is well known that antibodies against EBA-
175 inhibit binding to glycophorin A and thus prevent merozo-
ite invasion of erythrocytes.  3,  4   The gene encoding EBA-175 is 
located on chromosome 7 and is comprised of four exons and 
seven regions termed I–VII that include three cysteine-rich 
regions (F1, F2, and C).  13–  15   Exon 1, located in region II, has 
four regions that encode a repeated sequence of two Duffy 
binding-like domains (F1 and F2). The two domains are sepa-
rated by highly divergent dimorphic region III, through the 
insertion of either a 342-basepair segment in FCR-3 strains 
(F-loop) or a 423-basepair segment in CAMP strains (C-loop). 
The relevance of the F/C segments is not well known, but the 
proportions have been shown to vary among natural para-
site populations in Africa.  16,  17   Previous studies analyzing the 
influence of this dimorphism on clinical status and outcomes 
in children from Gabon  15,  17   showed low prevalence of mixed 
C-/F-infection in asymptomatic children than in symptomatic 
persons. 
  Apical membrane antigen is an 83-kD type I integral mem-
brane protein with a 55-amino acid cytoplasmic segment and 
a 550-amino acid extracellular region that can be divided 
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into three domains on the basis of intra-domain disulfide 
bonds. Although its function is still not well characterized, it 
is expressed in the late schizont stage of the parasite and is 
required for merozoite invasion of erythrocytes and sporozoite 
invasion of hepatocytes. Antibodies against AMA-1 have been 
shown to block parasite invasion of human erythrocytes.  18  
  Plasmodium flaciparum ama-1   is highly polymorphic,  19,  20  
and the domain I has been shown to contain most of the poly-
morphism.  19,  21   Based on restriction fragment length polymor-
phism (RFLP) analysis, domain I can be subdivided into four 
groups termed I, II, III, and IV.  20   Protective responses induced 
by this antigen are strain specific, suggesting that these poly-
morphisms have arisen by diversifying selection.  22  
  Plasmodium falciparum   MSP-3 is encoded by a single locus 
on parasite chromosome 10, and is an important target for 
protective immunity because antibodies against it could pre-
vent erythrocyte invasion by merozoites.  23   Merozoite surface 
protein 3 is a member of a heteromeric protein complex asso-
ciated with the merozoites outer membrane involved in inter-
actions with the acidic basic repeat antigen, or ABRA (also 
known as MSP9).  23–  25   Structurally, the MSP-3 protein is com-
posed of three blocks of tandemly alanine-repeated heptads 
and separated by short stretches of non-repetitive sequence 
unrelated to the heptad-repeat. Previous analysis of the   msp -3 
gene from   P. falciparum   isolates showed that polymorphism 
in the gene is predominantly confined to sequence in the 
N-terminal extremity within and flanking the heptad-repeat 
previously identified as a site of antigenic diversity among 
MSP-3 polypeptides.  24   The C-terminal domain (correspond-
ing to aa 196–379 in the K1 allele sequence) is highly con-
served among various parasite isolates.   24–  26   There are several 
sequences differences among   msp-  3 alleles, but the sequence 
polymorphism define 2 major allele classes (K1 like and 3D7 
like), which show only limited recombination.  27  
  The purpose of this study was to determine the distribution 
of major allele classes for three   P. falciparum   candidate vac-
cine antigens (AMA-1, EBA-175, and MSP-3) across varied 
eco-epidemiologic zones in central and West Africa. Field iso-
lates were obtained from symptomatic persons in five coun-
tries and were typed with respect to vaccine antigen candidate 
major allele classes as defined by RFLPs. Knowledge of the 
distribution of polymorphic malaria antigens across this broad 
geographic range may contribute to the rational development 
of a malaria vaccine. 
   MATERIAL AND  METHODS 
    Study sites and study population.     The study was conducted 
in different sites in five countries (  Figure 1  ): Cameroon and 
Republic of Congo in central Africa; and Burkina Faso, Ghana, 
and Senegal in West Africa. 
   Burkina  Faso.     Samples were collected from the Saponé 
Marché and Kounda communities health clinics located 
within an 8-km radius in the Saponé Health District situated 
approximately 50 km southwest of Ouagadougou, the capital 
of Burkina Faso. The Saponé Health District is located at 
12°13′N, 1°48′W and has approximately 80,000 inhabitants, 
most (> 95%) from the Mossi ethnic group. The number of 
children less than five years of age in the health clinics area of 
the two communities was approximately 465. All malaria cases 
were freely managed by using artemisinin-based combination 
therapy (Coartem  ®  ; Roche, Basel, Switzerland) during a one-
year longitudinal follow-up study. Malaria transmission is 
perennial and seasonal in the district, and there is a peak during 
the rainy season (May–October). The entomologic inoculation 
rate was estimated to be 200 infected/bites/person/year in the 
study area.  28   The incidence of clinical malaria cases in children 
less than five years of age living in Saponé Health District was 
estimated to be 0.7 episodes/child-year (Sirima BS and others, 
unpublished data). 
   Cameroon.     The study was carried out in health centers 
in three localities (Nkolbisson, Etoug-egbe, and Mfou) in 
Yaounde. The three localities have equal malaria transmission 
intensities. Yaounde is located at 3°52′0 N, 11°31′0 E. The 
population is comprised of heterogeneous ethnic backgrounds 
from every region of the country. Malaria is the primary 
cause of morbidity in these localities. Maximal transmission 
(EIR  > 200 infected bites/person/year) occurs during and 
immediately after the two rainy seasons (March–June and 
September–November). 
   Republic  of  Congo.     The study was conducted at the 
Tenrikyo Integrated Health Center, which is located within 
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the Makélékélé Health District in Brazzaville, Republic of 
Congo. Brazzaville is located situated between 4°13′S and 
4°18′S and 15°13′E and 15°18′E. The rainy season lasts eight 
months (October–May), and the dry season last four months 
(June–September).  29   Malaria transmission is mediated mainly 
by   Anopheles gambiae  . Other vectors, such as   An. moucheti , 
  An. funestus  , and   An. nili  , are also found.  30  
   Ghana.     The study was conducted at the Navrongo War 
Memorial Hospital in the Kassena-Nankana District (northern 
Ghana) and the Begoro District Hospital in the Fanteakwa 
District (southern Ghana). The Kassena-Nankana District is 
located in the Upper East Region along the Ghana–Burkina 
Faso border. The district is hot and dry and is located in the 
Guinea Savannah Belt. Navrongo, the district capital, is located 
at 10°53′5″N, 1°5′25″W. Estimated malaria attack rates in the 
district are approximately 4.7 and 7.1 infections/person/year 
for the dry and wet seasons, respectively.  31  
  The Fanteakwa District is located in the Eastern Region of 
Ghana. Begoro, which is the district capital of the Fanteakwa 
District, is located at 6°22′N, 0°23′W, approximately 150 km 
north of Accra, the capital of Ghana. Malaria is known as 
the most prevalent disease reported at the Begoro District 
Hospital. 
   Senegal.   The study took place in the rural community of Keur 
Socé located approximately 17 km south of Kaolack. Keur 
Socé is situated at 14°33′46.14″N, 15°35′30.53″W. Children less 
than five years of age represent approximately 20% of the 
population. Malaria transmission in this locality is seasonal. 
Entomologic inoculation rates vary between 9 and 12 infected 
bites/person/night during the high transmission season. 
    Ethical considerations.   Ethical clearances and administrative 
authorizations were obtained by the competent Ethical Review 
Committees and issuing bodies for the respective studies 
with approval including consent to use samples for malaria 
related studies. These committees were the Health Research 
Ethics Review Committee in Burkina Faso, the National Ethic 
Committee in Cameroon, the Ministry of Health and the 
Ministry of Scientific Research in the Republic of Congo, the 
Institutional Review Board of the Noguchi Memorial Institute 
for Medical Research, University of Ghana, Legon, Ghana, 
and the Health Ethical Committee based at the Ministry of 
Health in Senegal. The purpose of the study and all anticipated 
risks and benefits were clearly explained to the participants. 
Written informed consent and assent were obtained from the 
participants or their guardians, and participation in the studies 
was strictly voluntary. 
   Sample  collection.     Sampling was conducted at clinics and 
hospitals. Samples collection criteria were   P. falciparum -
infected, symptomatic, voluntary children or infants with 
malaria living in the five study countries irrespective of parasite 
density. Symptomatic malaria includes uncomplicated malaria 
and severe malaria as per the World Health Organization 
malaria definition. To limit any bias related to data collection, 
samples were collected between during two consecutive 
years during 2007–2009. In Ghana, samples were obtained in 
2007 and 2008 from children 6–60 months of age who were 
enrolled in a study to assess the therapeutic efficacy of anti-
malaria drugs.  32   In Burkina Faso, the study samples were 
obtained from children 6–59 months of age as part of a malaria 
morbidity and mortality longitudinal study carried out in 2007 
and 2008. Samples from Senegal were obtained in 2007 and 
2008 from children 6–59 months of age during an antimalarial 
drug clinical trial. In Cameroon, samples were obtained in 
2009 from children less than 15 years of age involved in a study 
aimed at assessing the genetic diversity of polymorphic malaria 
candidate vaccine antigens. In Congo, samples were obtained 
from children less than 15 years of age during a sulfadoxine-
pyrimethamine and chloroquine efficacy assessment in 2009. 
  Samples were obtained at clinics or hospitals from 659 
  P. falciparum  -infected symptomatic children with malaria liv-
ing in five countries in central and west Africa: 231 isolates 
from Saponé Health District (Burkina Faso), 105 isolates from 
Keur Socé (Senegal), 122 isolates from Yaounde (Cameroon), 
100 isolates from the Republic of Congo, and 101 isolates from 
Begoro (southern Ghana) and Navrongo District Hospitals 
(northern Ghana). 
  Thick and thin blood smears were prepared for micro-
scopic identification of   P. falciparum  . Whole blood from 
  P. falciparum -positive persons was blotted on sterile, Whatman 
(Maidstone, United Kingdom) III filter paper, stored dry at 
room temperature and protected with a silica gel desiccant, 
and archived for later   P. falciparum   DNA isolation. 
   Microscopic  examination.     Giemsa-stained blood smears 
were microscopically examined to identify mono-infections 
with   P. falciparum  . Slides were examined by experienced 
microscopists in each study site. A person was considered 
positive if malaria parasites were detected in the blood smear 
and negative if parasites were not detected after examining 
200 oil-immersion fields of a thick blood smear. 
   Extraction  of   P. falciparum   DNA.     Plasmodium falciparum  
DNA was isolated from archived blood spots by using two 
methods: Tris-EDTA (TE) with heat  33   and the Qiagen (Valencia, 
CA) blood blot extraction method with QIAmp DNA blood 
mini kits. For the TE and heat method, approximately 5 mm 
of the blood spot per sample was cut with a sterile disposable 
blade and placed in 1.5 mL Eppendorf (Hamburg, Germany) 
tube. Sixty-five microliters of TE buffer (10 mM Tris, pH 8.0, 
0.1 mM EDTA in distilled water) was added and the tube was 
incubated at 50°C for 15 minutes. The paper was gently pressed 
several times at the bottom of the tube with a new and sterile 
pipette tip for each sample. The tube was again incubated at 
95°C for 20 minutes and centrifuged for 3 seconds to remove 
condensation from the lid. The DNA extracts were aliquoted 
into sterile tubes. Extraction by the Qiagen kit method was 
conducted according to the manufacturer’s protocol. All 
DNA samples were stored at –20°C before genotyping with a 
polymerase chain reaction. 
   PCR  amplification.    For   eba-175  , nested PCR products were 
analyzed for amplification fragment length polymorphisms.  34  
For   msp-3  , semi-nested PCR was used to produce DNA 
fragments. The  ama-1  haplotypes were analyzed by using PCR-
RFLP.  20  Oligonucleotide primer sequences for the primary and 
secondary amplifications are listed in   Supplemental Table 1  . 
  The first-round PCR amplifications were performed in a 
final volume of 25 μL that contained 1 μM of each primer, 
1 unit of Taq DNA polymerase (Invitrogen, Carlsbad, CA), 
2.5 μL of 10× PCR buffer (Invitrogen), 2.0 mM MgCl  2,   200  μM 
dNTP (Invitrogen), and 5 μL of DNA template extracted from 
blood. The second round amplification reactions were per-
formed similarly to the first with 2.5 μL of the first PCR prod-
uct as DNA template in 25 μL total reaction volume (  eba-175  
and   msp-3  ). Second-round reaction mixtures for   ama-1   were 
performed in a final volume of 50 μL that contained 5 μL of 
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(Invitrogen), and 5 μL of DNA template. All reactions were 
performed using 96-wells plate on a classic 96-well thermocy-
cler (Eppendorf). 
  Cycling conditions for the first and second PCR cycles of 
  eba-175   and   msp-3   were 94°C for 30 seconds, 54°C for 30 sec-
onds, and 68°C for 2 minutes, followed by a final extension at 
68°C for 5 minutes, for a total of 30 and 40 cycles respectively. 
For   ama-1  , the amplification cycles were 95°C for 2 minutes 
30 seconds, 51°C for 30 seconds, and 68°C for 45 seconds, fol-
lowed by a final extension at 68°C for 5 minutes for 30 cycles 
for the first nested PCR and 35 cycles for the second PCR. 
  Purified DNA from   P. falciparum   3D7 (MRA-102G), HB3-
B2 (MRA-149G), Dd2 (MRA-152G), 7G8 (MRA-153G), 
W2 (MRA-157G), K1 (MRA-159), V1/S (MRA-176), and 
FCR3 (MRA-731) strains was provided by the Malaria 
Research and Reference Reagent Resource Center, American 
Type Culture Collection (Manassas, VA) and used as positive 
controls during the amplification reactions. 
  The second amplification products from   eba-175   and   msp-3  
were directly separated by electrophoresis on a 2.0% ethid-
ium bromide agarose gel and visualized on a GEL LOGIC 
220 UV-Transillumination Imaging System (Carestream, 
Rochester, NY). The second   ama-1   amplification product was 
digested by using three restriction enzymes (  Mse   I,   Ssp   I, and 
  BfCU   I), which generated digestion fragments specific for the 
D7, K1, and HB3/7G8   ama-1   allele classes, respectively. 
   Data  interpretation.     Positive controls were used to scored 
and interpreted fragment sizes. The   msp-3   K1 allele was 
identified as a single approximately 500-basepair fragment, and 
the   msp-3   3D7 allele was identified as a single approximately 
400-basepair fragment. Any other   msp-3   fragments of 
different sizes were also reported. The CAMP allele was 
identified as a single approximately 714-basepair fragment, 
and the FCR3 allele was identified as a single approximately 
795-basepair fragment. Mixed infections were defined as the 
simultaneous presence of K1 and 3D7   msp-3   alleles or the 
F and C   eba-175   fragments in the same sample. The   ama-1   K1, 
3D7, and HB3/7G8 alleles were identified as single fragments 
of 285, 400, and 335 basepairs, respectively, when subjected to 
digestion with   Mse   I,   Ssp   I, and   BfuC   I, respectively. 
   Statistical  analysis.     Allelic data were analyzed by using 
GenAlex 6,  35   Arlequin  v3.1, 36   and Epi Info v6.04a (Centers 
for Disease Control and Prevention, Atlanta, GA). Data were 
analyzed by using chi-square or Fisher’s exact tests; we used a 
statistical significance threshold of   P   < 0.05. Allele frequencies 
were estimated in GenAlEx (  http://www.anu.edu.au/BoZo/
GenAlEx/  ). Genetic diversity was estimated by determining 
the heterozygosity based on the three antigens combined, 
where heterozygosity (  h  ) = 1 − ∑   pi  2   ranged from 0 to 1, where 
  pi   is the frequency of the   i-  th     allele. The   t  -test was used to 
compare mean heterozyosity among the different sites. 
  To compare allele frequencies along an east–west transect, 
data were pooled into three geographic groups: Cameroon 
and Republic of Congo (east), Burkina Faso, southern and 
northern Ghana (middle) and Senegal (west). 
  We used Nei’s standard genetic distance, and the Mantel 
test to measure the genetic differentiation of genes across the 
different study sites. The option of the Mantel test we used 
enables a statistical relationship between the elements of any 
two distance matrices with matching entries. This typical appli-
cation includes testing for isolation-by-distance for which one 
might compare Nei genetic distance matrix with the geographic 
distance matrix for the respective populations. Typically, it is 
reported as an XY graph with log-distance versus linearized 
Fest (in our case using binary data it is linear zed-Phi). We 
examined how genetic variation was partitioned among geo-
graphic units by using analysis of molecular variance.  37  
    RESULTS 
  The main goal of this study was to analyze separately and in 
combination three polymorphic antigen genes across west and 
central Africa to identify differences in allele frequency and 
genetic diversity and to determine whether geographic dis-
tance contributes to genetic differentiation across our study 
region. 
  Of the 659 confirmed   P. falciparum   samples obtained from 
the five countries, 418 samples were successfully scored for 
  eba-175  , 535 for   msp-3  , and 318 for   ama-1  . Two hundred sixty-
six samples were used in the combined datasets analyses. To 
minimize the confounding effects of missing data, inclusion 
in the combined dataset was limited to samples with missing 
data for no more than one marker. Failure to amplify domains 
from a fraction of the patient samples (241 for   eba-175  ; 124 for 
  msp-3  , and 341 for   ama-1  ) was attributed to variance in para-
sitemia, quality of the filter paper used, and extraction effi-
ciency from the paper. All these PCR failures were excluded 
from further analysis. 
  A total of 97 mixed infections, or 15% of all infections sam-
pled, were identified on the basis of multiple   eba  -175 or   msp -3 
alleles. This number is likely an underestimation because all 
markers were not successfully scored for all isolates. Most 
of the mixed infections (> 40%) were from rural villages in 
Burkina Faso. Mixed infections were included in all further 
analyses. 
    Allele prevalences across the study area.   Allele  prevalences 
were analyzed for each locus to assess variation across the 
study area. The F-loop allele accounted for > 50% of   eba-175  
alleles in Burkina Faso, Republic of Congo, and Cameroon, 
where it was twice as common as the C-loop allele (  Table 1  ). 
In general, the F-loop allele showed a clinal decrease in 
prevalence moving from east to west (  Figure 2A  ). No such 
trends in allele prevalence were observed for the other two 
markers, and they appeared to be remarkably consistent 
across the study area (  Figure 2B   and C). Rare   eba -175  alleles 
were observed in most but not all study sites. The   eba-175  
400 bp allele was more prevalent in Ghana and Senegal 
(> 10%) than in Burkina Faso, Cameroon, and Republic of 
Congo (< 2%) (  Figure 2A  ). Despite the trend observed for 
the F-loop allele, there was no statistical difference in the   eba-
175   allele prevalence among countries or between geographic 
regions, with the exception of the 400  bp   rare allele, which was 
significantly more common in southern Ghana (  Table 1   and 
 Figure  2A ). 
       T h e    msp-3   allele classes (K1 and 3D7 types) showed com-
parable prevalence in all countries (  Table 1   and   Figure 2B  ). In 
contrast, the rare 350  bp   allele was observed in all countries 
but was approximately three times more common in Senegal 
(preva lence = 11%) ( Table 1  and  Figure 2B ). The other rare  msp-
  3 allele appeared to be restricted to Cameroon and accounted 
for only 2% of alleles from that country ( Table 1  and  Figure 2B ). 
In addition, the comparison of   ama-1   alleles prevalence among 
geographic regions showed a significant difference (  P   = 0.03) 
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prevalence in the eastern portion of the study region (Republic 
of Congo and Cameroon) (  Table 1   and   Figure 2C  ). 
   Antigen  genetic  diversity.     Mean heterozygosity (  h )  was 
calculated from allele frequencies to compare genetic 
diversity in the different study sites. For the combined dataset, 
the number of alleles ranged from 8 to 10. One   msp-3   allele, 
(  msp3  > 500  bp ) was exclusively present in Cameroon ( Figure 3 ). 
The mean heterozygosity for the combined dataset did not 
differ greatly among the study sites (range = 0.313–0.375). In 
general, the heterozygosity in   ama-1   was higher than in the 
other two genes. In addition, individual gene heterozygosities 
did not differ among study sites, with the exception of southern 
Ghana (  Figure 3  ), where there was a noticeable and significant 
decrease   ama-1   heterozygosity (  P   < 0.0001, by   t  -test) and a 
corresponding spike for   eba-175   ( P   < 0.001). 
    The overall heterozygosity was significantly higher in 
Senegal (  P   < 0.0001, by   t  -test) and for   ama-1 ,   eba-175 ,  and 
  msp3  individually. However, because the southern Ghana sam-
ple size (5.6% combined [15 of 266]) was small (n = 15, com-
bined marker dataset), our heterozygosity estimate for this 
site is probably not an accurate reflection of the true value. 
      Genetic differentiation of antigen across the study 
area.     Analysis of molecular variance enabled hierarchical 
partitioning of genetic variation within and among study sites 
and among pre-defined geographic regions (west: Senegal; 
middle: northern Ghana, southern Ghana, and Burkina 
Faso; east: Republic of Congo and Cameroon). Most genetic 
variation was captured within individual populations (97%), 
and there was little variance among a population within a 
region (3%) and no partitioning among geographic regions 
(  Table 2  ). Nei’s Standard Genetic Distance was used to assess 
genetic differentiation among study sites. In general, genetic 
distance values were low (approximately 0;   Table 3  ). Genetic 
distance between southern Ghana and the others study sites 
was generally higher, although still approximately 0 (  Table 3  ). 
The Mantel test was used to assess the influence of geographic 
distance on the genetic diversity of the antigens sampled. It 
showed a non-significant trend of greater genetic distance 
with decreasing geographic distance. Close examination 
of the results showed that a single data point, representing 
the comparison of northern Ghana with Burkina Faso, is 
primarily responsible for this trend because these two sites are 
genetically distinct but geographically close (approximately 
135 km) (  Figure 4  ). These analyses indicate that the major 
allele classes are homogeneously distribution across the study 
region. 
             DISCUSSION 
  Plasmodium falciparum   is known to exhibit extensive 
genetic diversity, particularly among surface antigens that have 
been under selective immune pressure and historically consid-
ered as the main targets of subunit vaccines. Unfortunately, 
this extreme genetic diversity poses a major challenge for 
effective vaccine development because it could lead to vac-
cine-resistant malaria with non-vaccine type parasites grow-
ing in frequency within vaccinated populations.  5   Therefore,  to 
design a vaccine that is efficacious against any natural   P. falci-
parum   infection, multiple allelic forms of an antigen need to 
be incorporated in a vaccine formulation.  19,  38  
  The present study was designed to assess the distribution of 
major allele classes for three malaria vaccine candidates in a 
number of study sites across a geographic region spanning cen-
tral and West Africa. Although collection protocols were not 
standardized across study sites, active case detection was used 
at all sites, and samples were collected within the same three-
year time frame. In addition, all molecular methods and gel 
interpretations were standardized and conducted in the same 
laboratory at the same time. The markers used in this study 
did not have the resolution to measure the extensive genetic 
diversity known to exist for these surface antigens, but rather 
provides a pre-vaccine, baseline assessment of the distribution 
of major allelic classes. Our results address the feasibility of 
deploying a single vaccine throughout this large geographic 
region, and highlight the challenges posed by the considerable 
genetic diversity of these surface antigens. 
  Although the   eba-175   F-loop allele clearly predominates 
in the eastern portion of our study region (Cameroon and 
Republic of Congo), there is no one allele that is most com-
mon throughout the rest of the study area. The predominance 
observed in F-loop allele was similar to previous observations 
made in other parts of Africa.  15,  17,  39   In Senegal, frequencies of 
the two alleles (C-loop and F-loop) were not statistically dif-
ferent, which is consistent with a previous report from central 
and southern Senegal.  40  
 The   msp-3   allele classes (K1 and 3D7 type)  26   result from 
many amino acid substitutions. These two major allelic classes 
showed a balancing frequency throughout the study region, 
 Table 1 
    Erythrocyte binding antigen-175, merozoite surface protein-3, and apical membrane antigen allele prevalence for countries and regions in Africa   
    *     eba175 = erythrocyte binding antigen 175; bp = basepair; msp3 = merozoite surface protein 3; ama1 = apical membrane antigen-1.  
  †     P   value for comparison of allele frequency distributions among the three regions: East versus Middle versus West.   























eba175_F_loop 33 (58.9) 42 (60.9) 12 (46.2) 17 (50) 91 (55.2) 51(45.9) 0.5 51 (45.9) 120 (51.5) 75 (60.0) 0.09
eba175_C_loop 20 (35.7) 20 (29.0) 14 (53.8) 10 (29.4) 62 (37.6) 39 (35.1) 0.2 39 (35.1) 86 (36.9) 40 (32.0) 0.7
eba175–400bp 0 (0) 3 (4.3) 2 (0.08) 7 (20.6) 3 (1.8) 14 (12.6) 0.00001  ‡  14 (12.6) 12 (5.2) 3 (2.4) 0.003  ‡ 
eba175–360bp 3 (5.4) 4 (5.8) 0 (0) 6 (17.6) 9 (5.5) 7 (6.3) 0.1 7 (6.3) 15 (6.4) 7 (5.6)   0.9 
msp3_K1 46 (51.7) 44 (46.8) 16 (44.4) 20 (44.4) 111 (50.2) 45 (40.5) 0.2 45 (40.5) 147 (47.9) 90 (49.2)   0.4 
msp3_3D7 39 (43.8) 46 (48.9) 21 (58.3) 26 (57.8) 105 (47.5) 53 (47.8) 0.7 53 (47.8) 152 (49.5) 85 (46.4)   0.8 
msp3–350bp 4 (4.5) 2 (2.1) 0 (0) 3 (0.06) 5 (2.3) 13 (11.7) 0.002  ‡  13 (11.7) 8 (2.6) 6 (3.3) 0.0002  ‡ 
msp3–500bp 0 (0) 2 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) – 0 (0) 0 (0) 2 (1.1) –
ama1_K1 42 (40.8) 44 (37.6) 14 (63.6) 14 (38.9) 33 (27.3) 30 (37.0) 0.003  ‡  30 (37.0) 86 (39.1) 0.1
ama1_HB3 39 (37.9) 45 (38.5) 9 (52.9) 20 (74.1) 47 (38.8) 25 (30.9) 0.06 25 (30.9) 76 (36.7) 84 (38.2) 0.5
ama1_3D7 22 (21.4) 28 (23.9) 8 (36.4) 21 (63.4) 41 (33.9) 26 (32.1) 0.2 26 (32.1) 70 (33.8) 50 (22.7) 0.03  ‡ 281 MALARIA VACCINE ANTIGEN DIVERSITY IN WEST AND CENTRAL AFRICA
 Figure  2 .      A  , Distribution of erythrocyte binding antigen-175 alleles.   B  , Distribution of merozoite surface protein-3 alleles.   C  , Distribution of 
apical membrane antigen-1 alleles.       282 SOULAMA AND OTHERS
and this was also reflected in the equivalent   msp-3   heterozy-
gosity values observed across sites. We observed additional but 
less common,   msp-3   alleles (350 bp and 500 bp), which high-
lights the existence of significant alternative polymorphisms, 
as suggested by Polley and others  .  41   The comparable diver-
sity among countries in the present study confirmed previous 
results showing that the major   msp-3   dimorphic allele classes 
were maintained intact at a low frequency of recombination.  41  
  The isolates of   P. falciparum   in our study belonged to three 
of the four   ama-1   allele classes previously identified based 
on the hypervariable region. The fourth allelic class was not 
observed in our study and is presumed absent in sub-Saharan 
Africa. Polymorphism analysis of   ama-1   in the Amazon Basin 
in Peru identified three of the four   ama-1   allelic classes,  11   and 
analyses in India identified only two classes.  42   In the present 
study, the three alleles had roughly equivalent frequencies 
throughout the study region, with the exception of northern 
Ghana. Pooling data by region showed that the  ama-1  3D7-like 
allele was less common in the eastern region, which may have 
been caused by a directional selection for humoral immune 
response.  19,  40   In general,   ama-1   diversity was high and compa-
rable across the study sites even where there were regional 
differences in the prevalence of the different allelic classes and 
within-class variability, which may pose a problem for a vac-
cine based on this antigen. Although a remarkable conserva-
tion of the AMA-l molecule has been previously reported,  20,  43  
it is important to understand the extent to which variation in 
  ama-1  , which we were not able to detect by using RFLPs in 
the present study, may compromise vaccine development. It 
is well known that the total repertoire of circulating   ama-1  
alleles is probably large.  20  
  Most of the observed genetic variance was not related to 
regional difference but attributed to variation within study 
sites. In addition, geographic distance did not contribute to 
antigen genetic distance. It is highly unlike that unrestricted 
gene flow across such a large geographic region is responsi-
ble for these patterns. Our data showed the presence of the 
main allele classes of   eba-175 ,   msp-3   and   ama-1   at high and 
comparable frequencies throughout the study region. The lack 
of genetic differentiation or isolation-by-distance is probably 
caused by balancing selection. It is likely that immune selec-
tion for maximal diversity has overwhelmed any geographic 
partitioning we might otherwise have observed by using neu-
tral markers. 
  Each of the target loci is currently in vaccine trials intended 
for populations in sub-Saharan Africa where the number of 
malaria cases identified in the past 10 years shows little evi-
dence of decreasing.  1   The genetic diversity and relatively bal-
anced distribution of allele classes provides evidence that 
an effective vaccine should necessarily account for different 
allelic classes in combination, although this could be challeng-
ing with regards to product development.  44   If vaccines based 
on universally conserved subunit targets were to be used, field 
monitoring of known and novel allelic polymorphisms associ-
ated with the target before and after vaccination will provide 
important information on vaccine epidemiology and immune 
selection. 
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 Table 2 
    Hierarchical analysis of genetic variance among regions in Africa 
(Senegal, Burkina Faso, and Ghana, and Cameroon and Republic 
of Congo) and populations within regions   
Variance component, variance %, total   P 
Among regions: 0, 0%, 0.880
Among populations within regions: 0.06, 3%, 0.030
Within populations: 2.203, 97%, 0.020
 Table 3 
    Pairwise population matrix of Nei’s genetic distance among sampling 
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